<DOC>
	<DOCNO>NCT00309881</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving one drug ( combination chemotherapy ) together rituximab may kill cancer cell . PURPOSE : This phase II trial study well give combination chemotherapy together rituximab work treat patient chronic lymphocytic leukemia ( CLL ) respond fludarabine ( closed entry 10/2006 ) , CLL autoimmune hemolytic anemia , Richter transformation .</brief_summary>
	<brief_title>Combination Chemotherapy Rituximab Treating Patients With Chronic Lymphocytic Leukemia ( CLL ) That Did Not Respond Fludarabine , CLL With Autoimmune Haemolytic Anemia ( AIHA ) Richter 's Transformation ( RT )</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy , term rate quality remission , chemotherapy comprise cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone , rituximab ( CHOP-R ) patient fludarabine-refractory chronic lymphocytic leukemia ( CLL ) ( close accrual 10/2006 ) , CLL autoimmune hemolytic anemia , Richter transformation . - Determine incidence infection patient CHOP-R regimen . Secondary - Determine toxicity regimen patient - Determine progression-free overall survival patient treat regimen . OUTLINE : This prospective , multicenter study . Patients stratify accord disease ( chronic lymphocytic leukemia ( CLL ) ( close accrual 10/2006 ) v CLL autoimmune hemolytic anemia v Richter transformation ) . Patients receive cyclophosphamide IV , doxorubicin hydrochloride IV , vincristine IV day 1 oral prednisone day 1-5 . Patients also receive rituximab IV day 1 second course subsequent course . Treatment repeat every 21 day 6 ( patient CLL ) 8 ( patient Richter 's transformation ) course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 75 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis previously treat chronic lymphocytic leukemia ( CLL ) meeting follow criterion : Binet stage B ( Rai stag I II ) Binet stage C ( Rai stag III IV ) disease Rapid disease progression , symptomatic enlarge lymph node , severe Bcell symptom CLL autoimmune hemolytic anemia allow Richter transformation allow PATIENT CHARACTERISTICS : Life expectancy &gt; 3 month ECOG performance status 03 No severe organ dysfunction No prior concurrent neoplasms PRIOR CONCURRENT THERAPY : No 4 prior chemotherapy regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>